DBV Technologies (DBVT) Net Cash Flow (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Net Cash Flow of -$53.1 million for Q2 2026, down 163.9% year-on-year from $83.1 million in Q2 2025, and down 234.43% on a QoQ basis from $39.5 million in Q1 2026.
DBV Technologies (DBVT) Net Cash Flow (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Net Cash Flow for 7 consecutive years, with -$53.1 million the latest figure, recorded in Q2 2026.
- Quarterly Net Cash Flow fell 163.9% year-over-year to -$53.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $77.0 million (up 159.74% YoY) and the FY2025 annual result came in at $153.6 million, up 246.81% from the prior year.
- Net Cash Flow slipped to -$53.1 million in Q2 2026 per DBVT's latest filing, from $39.5 million in the prior quarter.
- Over the last five years, Net Cash Flow for DBVT reached as high as $184.9 million in Q2 2022 and fell as low as -$53.1 million in Q2 2026.
- A 5-year average of $5.6 million and a median of -$20.4 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow slumped 1200.0% — and 2025, when it soared 1242.17%.
- Year by year, Net Cash Flow stood at -$24.2 million in 2022, then surged by 41.9% to -$14.1 million in 2023, then increased by 23.31% to -$10.8 million in 2024, then surged by 1242.17% to $123.2 million in 2025, then sank by 143.11% to -$53.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$53.1 million, $39.5 million, and $123.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -53.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.10 Mn |
| Jun 30, 2026 | -53.10 Mn |
| Mar 31, 2026 | 39.50 Mn |
| Mar 31, 2026 | 39.50 Mn |
| Dec 31, 2025 | 123.17 Mn |
| Dec 31, 2025 | 123.17 Mn |
| Sep 30, 2025 | -32.54 Mn |
| Sep 30, 2025 | -32.54 Mn |
| Jun 30, 2025 | 83.10 Mn |
| Jun 30, 2025 | 83.10 Mn |
| Mar 31, 2025 | -20.10 Mn |
| Mar 31, 2025 | -20.10 Mn |
| Dec 31, 2024 | -10.78 Mn |
| Dec 31, 2024 | -10.78 Mn |
| Sep 30, 2024 | -22.56 Mn |
| Sep 30, 2024 | -22.56 Mn |
| Jun 30, 2024 | -34.42 Mn |
| Jun 30, 2024 | -34.42 Mn |
| Mar 31, 2024 | -36.89 Mn |
| Mar 31, 2024 | -36.89 Mn |